Plasmodium vivax vaccine research - we've only just begun
- Author(s)
- Tham, WH; Beeson, JG; Rayner, JC;
- Details
- Publication Year 2017-11-27,Volume 47,Issue #2-3,Page 111-118
- Journal Title
- Int J Parasitol
- Publication Type
- Journal Article
- Abstract
- Plasmodium vivax parasites cause the majority of malaria cases outside Africa, and are increasingly being acknowledged as a cause of severe disease. The unique attributes of P. vivax biology, particularly the capacity of the dormant liver stage, the hypnozoite, to maintain blood-stage infections even in the absence of active transmission, make blood-stage vaccines particularly attractive for this species. However, P. vivax vaccine development remains resolutely in first gear, with only a single blood-stage candidate having been evaluated in any depth. Experience with Plasmodium falciparum suggests that a much broader search for new candidates and a deeper understanding of high priority targets will be required to make significant advances. This review discusses some of the particular challenges of P. vivax blood-stage vaccine development, highlighting both recent advances and key remaining barriers to overcome in order to move development forward.
- Publisher
- Elsevier
- Research Division(s)
- Infection And Immunity
- PubMed ID
- 27899329
- Publisher's Version
- https://doi.org/10.1016/j.ijpara.2016.09.006
- Open Access at Publisher's Site
ww.sciencedirect.com/science/article/pii/S0020751916302545- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2017-05-26 03:11:45
Last Modified: 2017-05-26 03:46:49